INTRODUCTION The ‘Progressive Supranuclear Palsy (PSP) Therapies Market by Treatment Type (Curative and Palliative / Symptomatic) and Key Geographic Regions (US, UK, Germany, France, Italy and Spain): Trends in ‘Global Industry and Forecasts, 2021-2030’ The report presents an in-depth study of molecules being evaluated at various clinical and non-clinical stages of development, for the treatment of progressive supranuclear palsy.
New York, December 10, 2021 (GLOBE NEWSWIRE) – Reportlinker.com announces the publication of the report “Progressive Supranuclear Palsy Therapies Market by Type of Treatment, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030” – https: / /www.reportlinker.com/p06189681/?utm_source=GNW
This report provides an in-depth analysis of the product pipeline and development companies, highlighting current treatment practices, emerging drugs, and individual therapies market share. In addition to other elements, the study includes a detailed assessment of the current market landscape, providing information on the phase of product development, molecule type, mechanism of action, route of administration, milestones. regulatory and other development activities.
One of the main objectives of the report was to estimate the size of the existing market, and the future opportunities of therapies for progressive supranuclear palsy, over the next decade. Based on several parameters, such as disease prevalence, anticipated uptake of planned therapies, and the likely selling price of these therapeutic products, we have provided educated estimates on how the market will develop for the period 2021- 2030.
SCOPE OF THE REPORT
A detailed assessment of the activity of the therapeutic pipeline and the therapeutic evaluation of products by stage of development, type of molecule, mechanism of action, type of treatment, designation of orphan drug and route of administration throughout the cycle of product development, including all clinical aspects and non-clinical stages.
An analysis of the overall developer landscape of the market, highlighting the contributions of industrial and non-industrial players, along with information on their year of establishment, company size, ownership and geographic location of their headquarters .
A case study of dormant, terminated and other programs; it presents a list of therapies that have been discontinued or do not have recent updates on their developmental phase transition. In addition, it presents a list of generic and non-generic drugs that can be explored as treatment options for progressive supranuclear palsy.
A detailed analysis of completed, ongoing and planned clinical studies, based on various relevant parameters, such as year of trial registration, trial phase, number of patients enrolled, design of the trial study, trial enrollment status and trial objective, highlighting major sponsors, type of organization, type of treatment, purpose of study and regional distribution of trials.
A detailed analysis identifying Key Opinion Leaders (KOLs), including a 2X2 analysis to assess the relative experience of some KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) in this area .
Information on grants awarded to research institutes for projects related to progressive supranuclear palsy, during the period 2010 and 2021, on the basis of several important parameters, such as year of grant award, amount granted, the center of the administering institute, the period of support, the type of grant application, the object of the grant, the activity code, the area of interest, the section of study concerned and the type recipient organizations. In addition, it highlights the centers of popular funding institutes, prominent program officers and popular recipient organizations.
A detailed review of over 2,000 peer-reviewed scientific articles related to progressive supranuclear palsy research, which were published between 2009 and 2021, including an analysis based on parameters, such as year of publication, emerging areas of interest, most popular authors and key journals (in terms of number of articles published in this area and journal impact factor).
An analysis of the partnerships that have been established in the field, over the past seven years, covering research and development agreements, product / technology license agreements, product development agreements, mergers / acquisitions, agreements clinical trials and other relevant agreements.
Detailed profiles of the players engaged in the development of drug products / therapies for progressive supranuclear palsy, presenting an overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and enlightened future prospects.
An insightful analysis of the market forecast, highlighting the likely launch year of several late stage therapies, their global and regional sales projections, and the likely growth of the overall market through 2030. In order to provide From a detailed future perspective, our projections have been segmented between different types of treatment (curative, palliative / symptomatic) and key geographic areas (US, UK, Germany, France, Italy and Spain).
A collection of interview transcripts of discussions held with key industry stakeholders. We presented the details of the interviews conducted with Daniel Brennan (Business and Operations Advisor, NeuroTau) and Fabrizio Stocchi (Professor, IRCCS San Raffaele).
In the coming years, the market is expected to grow at a steady rate owing to the growing awareness of the disease and the growing interest of stakeholders to invest in this area.
More innovative therapeutic solutions are being developed by various industrial and non-industrial players, who are actively focusing on the challenges of treating progressive supranuclear palsy.
The significant impact on the size of the market can also be attributed to the contributions of several large pharmaceutical players actively involved in the evaluation of various therapeutic candidates in this area.
With various potential therapies under clinical investigation, a marked increase in the number of new market entrants is expected in the coming years.
ANSWERS TO KEY QUESTIONS
What are the current R&D trends related to progressive supranuclear palsy?
What are the main challenges facing the actors involved in this field?
What are the main therapies developed by companies in this field?
Who are the main industrial and non-industrial players in this market?
What are the contributions of the major pharma players in this field?
Which are the most active clinical trial centers?
Who are the main investors in this area?
Who are the main opinion leaders / experts in this field?
What types of partnership models are commonly adopted by industry players?
What factors are likely to influence the development of this future market?
How are current and future market opportunities likely to be distributed among key market segments?
Read the full report: https://www.reportlinker.com/p06189681/?utm_source=GNW
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001